It has a high affinity to GLP-1R, strongly activating the GLP-1R Gs cAMP pathway without inducing measurable -arrestin recruitment signaling, which indicates it is a fully biased agonist
Given the uncertainty of this initial clinical trial, additional studies exploring the effect of different GLP-1R agonists on alcohol drinking in overweight AUD patients are needed in the future
They can assess whether a slower titration schedule, a temporary dose reduction, or other interventions might be appropriate for your situation
#DiabetesCare #PrecisionMedicine #MetabolicHealth #LowerTheDose #HealthcareInnovation To view or add a comment, sign in In our recent publication in Diabetes, Obesity and Metabolism, together with Professors Kokkinos and le Roux, we articulate a perspective grounded in robust scientific evidence, yet one that is rarely expressed with candor in the public scientific discourse: that, as with any other chronic disease, pharmacotherapy should constitute the central pillar in the treatment of obesity, while other approaches retain an important but complementary role
